Evidence map›Paper›PMID 32706558›Full record

ArticleCritical care medicine2020

Optimizing the Risk-Benefit Balance of Thromboprophylaxis in Critically Ill Patients With Coronavirus Disease 2019.

Michaël Piagnerelli, Philippe Cauchie, Jean-Claude Wautrecht

Abstract readLetterComment
In one paragraph

Article in Critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Anticoagulants for people hospitalised with COVID-19: a rapid reviewThe Cochrane database of systematic reviews · 2022
    Pooled it
  2. Article
  3. Article
  4. Review
  5. The authors reply.Critical care medicine · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Michaël PiagnerelliIntensive Care, CHU-Charleroi Marie-Curie, Université Libre de Bruxelles, Charleroi, Belgium, and Experimental Medicine Laboratory, CHU-Charleroi, ULB 222 Unit, Université Libre de Bruxelles, Brussels, Belgium.
Philippe CauchieClinical Biology, Department of Haematology, CHU-Charleroi Marie-Curie, Université Libre de Bruxelles, Charleroi, Belgium.
Jean-Claude WautrechtDepartment of Vascular Diseases, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium, and Department of Cardiology, CHU-Charleroi Marie-Curie, Université Libre de Bruxelles, Charleroi, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CoronavirusCoronavirus InfectionsPandemicsPneumonia, ViralVenous ThromboembolismAnticoagulantsBetacoronavirusCOVID-19Critical IllnessHumansSARS-CoV-2Anticoagulants

Identifiers

PMID32706558
PMCPMC7375185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.